Analysts Set AstraZeneca PLC (NASDAQ:AZN) Target Price at $89.75

AstraZeneca PLC (NASDAQ:AZN) has been assigned a consensus recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $89.75.

Several equities research analysts have commented on AZN shares. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th.

AstraZeneca Trading Up 0.6 %

Shares of AZN stock opened at $68.60 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a market cap of $212.73 billion, a P/E ratio of 32.82, a PEG ratio of 1.13 and a beta of 0.46. The company has a 50 day moving average of $66.26 and a 200-day moving average of $74.28. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.87 earnings per share. Sell-side analysts anticipate that AstraZeneca will post 4.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. McClarren Financial Advisors Inc. raised its stake in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter worth $28,000. Albion Financial Group UT raised its position in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after buying an additional 248 shares in the last quarter. Groupama Asset Managment lifted its holdings in shares of AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in AstraZeneca in the third quarter worth $45,000. Institutional investors own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.